CA-WIND-RIVER
Wind River® , a global leader in delivering software for mission-critical intelligent systems, today announced that Hyundai Mobis, one of the world’s largest vehicle technology innovators and suppliers, and Hyundai AutoEver has signed an agreement to establish a strategic relationship that includes collaboration with Wind River Studio for the development of an automotive software framework and continuous test and test automation capabilities, as well as advanced software lifecycle management.
“As we move toward a more connected and autonomous future, software is at the center of enabling that reality,” said Avijit Sinha, chief product officer, Wind River. “Wind River Studio can help automotive leaders such as Hyundai Mobis and Hyundai AutoEver achieve a modernized development framework across cloud and edge, combined with software lifecycle management capability to enable them to accelerate their innovation and advance the software defined vehicle.”
“Hyundai Mobis plans to continue to introduce new services by adding future mobility technology to intelligent vehicles through extensive cooperation,” said Chang Jae-ho, senior vice president at Hyundai Mobis.
“Hyundai AutoEver plays the role of software specialist in the Hyundai Motor Group and is leading the team towards digital transformation to revolutionize software development and verification processes throughout vehicle development,” said Kim Seong-woon, vice president, head of the Software Quality Innovation Division at Hyundai AutoEver. “Through close cooperation with Wind River, we will strengthen the function and efficiency of Hyundai AutoEver’s software integrated development environment platform and virtual verification platform to contribute to innovation in vehicle software development by Hyundai Mobis and group companies.”
The auto industry is amid its most significant revolution in more than 100 years. Research from Forbes indicates that automotive leaders believe an intelligent systems approach is central to strategies that can deliver up to a 30% growth in revenue opportunities, and in five years’ time, many of the core requirements for intelligent systems in this industry will need to be in place.1
The collaboration will leverage each company’s specialties and experiences to develop a best-in-class software development infrastructure for next-generation connected automobiles. The companies will work closely on methodologies to accelerate the development and delivery of automotive systems, including enhanced continuous test capabilities and test automation in both simulated and real hardware-based environments and new customer test infrastructures making use of virtual device management.
The Hyundai AutoEver team will play a key role working with Wind River on a software integrated development environment platform and virtual verification platform.
Studio provides a cloud-native platform for the development, deployment, operations, and servicing of mission-critical intelligent systems. Studio delivers a full lifecycle management platform for intelligent systems at cloud scale. Studio enables development workflows that reduce development costs and accelerate capabilities for building, testing, and deploying on the edge.
More information about Wind River Studio is available at www.windriver.com/studio .
About Wind River
Wind River is a global leader in delivering software for mission-critical intelligent systems. For 40 years, the company has been an innovator and pioneer, powering billions of devices and systems that require the highest levels of security, safety, and reliability. Wind River software and expertise are accelerating digital transformation across industries, including automotive, aerospace, defense, industrial, medical, and telecommunications. The company offers a comprehensive portfolio supported by world-class professional services and support and a broad partner ecosystem. To learn more, visit Wind River at www.windriver.com .
About Hyundai MOBIS
Hyundai Mobis is the no.7 global automotive supplier, with annual sales of nearly $30 billion USD. The company was founded in 1977 and is headquartered in Seoul, Korea. Hyundai Mobis aims to become a lifelong technology partner for vehicles and people. The company has outstanding expertise in sensors, sensor fusion in ECUs and software development for safety control. The company’s products also include various components for electrification, brakes, chassis and suspension, steering, airbags, lighting, and automotive electronics.
About Hyundai AutoEver
Hyundai AutoEver, a mobility software provider that reliably, efficiently, and innovatively supports software and infrastructure across in-car and out-car areas, builds a mobility software platform to flexibly connect hardware and software, and is creating new value for the upcoming mobility ecosystem.
1 Forbes/Wind River, “Characteristics of Intelligent Systems,” 2021
Wind River is a trademark or registered trademark of Wind River Systems, Inc., and its affiliates. Other names may be the trademarks of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220503005428/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines to Present at Upcoming Investor Conferences28.10.2025 11:01:00 CET | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in fireside chats at two upcoming investor conferences: Guggenheim Second Annual Healthcare Innovation Conference on Monday, November 10, 2025 at 9:30 am EST; and Jefferies Global Healthcare Conference in London on Monday, November 17, 2025 at 4:00 pm GMT/11:00 am EST Live webcasts of these events can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com, https://hkexir.beonemedicines.com, https://sseir.beonemedicines.com. Archived replays will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through
Allianz Reports Safety Gains From Automated Mobility and Urges EU-Wide “Driving License” for Autonomous Vehicles28.10.2025 10:05:00 CET | Press release
Strategic priorities for safe autonomous mobility: Allianz calls for EU-wide uniform testing standards for the approval of autonomous vehicles, free access to accident- and safety-related in-vehicle data, and a joint European database for critical traffic situations.Predicted Safety Improvements: Allianz forecasts a 20 percent reduction in traffic accidents by 2035, increasing to over 50 percent by 2060, thanks to autonomous technology.Allianz claims analysis confirms that currently available autonomous braking assistance systems reduce the frequency of specific accidents by 66 percent.Consumer confidence and concerns: A survey across seven European countries reveals that while consumers expect safety improvements, they remain cautious about technological maturity and reliability.Victim protection is essential: Current liability and compulsory insurance models in motor insurance across most EU countries are suitable for autonomous vehicles. The promise of autonomous mobility is not jus
Ares Management and Slate Asset Management to Acquire Polish Real Estate Portfolio Valued at Over €300 Million From Trei Real Estate28.10.2025 09:15:00 CET | Press release
Ares Management Corporation (“Ares”) (NYSE: ARES), a leading global alternative investment manager, and Slate Asset Management (“Slate”), a global investor and manager focused on essential real estate and infrastructure, today announced that a joint venture between Ares Real Estate funds (“Ares Real Estate”) and Slate has agreed to acquire a portfolio of 36 properties in Poland (the “Portfolio”) from Trei Real Estate, an internationally active developer and asset manager. The Portfolio is valued at over €300 million. The Portfolio comprises 36 recently developed and fully occupied convenience-led retail parks strategically located across major Polish metropolitan areas near large catchment populations. The assets are inflation-protected through CPI-linked lease agreements underpinned by tenants with strong covenants. Most of the Portfolio’s income is derived from large regional retailers and essential goods providers, including grocers and pharmacies. “This transaction underlines our c
SK pharmteco Achieves Highest-Level My Green Lab Certifications Across Europe and Asia28.10.2025 09:00:00 CET | Press release
Green certification is the top tier of the globally recognized My Green Lab program for laboratory sustainability excellence SK pharmteco, a global contract development and manufacturing organization (CDMO), today announced a significant milestone in its commitment to environmental sustainability by earning four My Green Lab certifications, including two at the program’s highest level, Green. The remaining two labs earned Gold certification, reflecting advanced sustainability performance and progression toward full Green maturity. The certified facilities are Small Molecule Europe (Swords, Ireland) and Small Molecule Asia (Daejeon, South Korea), and the certifications cover the areas of Quality Control, Process Research & Development, and Analytical Research & Development. My Green Lab certification is widely regarded as the global standard for laboratory sustainability, recognized by the United Nations Race to Zero campaign for its rigor in advancing credible decarbonization. Green ce
Kemwell Biopharma Facility in Bengaluru Successfully Completes U.S. FDA Inspection for Commercial Drug-Product Manufacturing28.10.2025 07:00:00 CET | Press release
Milestone expands India’s role in global biologics manufacturing; collaboration with Cipla underscores commitment to quality and reliability Kemwell Biopharma Pvt Ltd (“Kemwell”), a leading global biologics Contract Development and Manufacturing Organization (CDMO), announced today that its drug-product manufacturing facility in Bengaluru has successfully completed a U.S. Food and Drug Administration (FDA) pre-approval inspection (PAI) and is now cleared for the commercial manufacturing and testing of injectable products destined for the U.S. market. This milestone marks the approval of the first product to get U.S. FDA clearance for commercial supply from Kemwell’s Bengaluru drug-product facility since the site became a dedicated biologics campus eight years ago. It demonstrates the company’s ability to meet stringent current Good Manufacturing Practice (cGMP) and aseptic drug-product manufacturing standards. “Achieving FDA clearance for commercial manufacturing from our Bengaluru sit
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom